1. Scrip
  2. >>Conferences
  3. >>ASCO

Roche’s First Anti-TIGIT Data Support Dual Checkpoint Inhibition Strategy

 
• By Mandy Jackson

Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.

Lungs operation puzzle concept: hands of surgeon with surgical instruments (tools) perform lungs surgery as a result of respiratory disease, pneumonia, tuberculosis, bronchitis, asthma, lung abscess
Tiragolumab plus Tecentriq worked best in PD-L1 high NSCLC • Source: Shutterstock

The first public data disclosure for Roche’s anti-TIGIT antibody tiragolumab in combination with the company’s PD-L1 inhibitor Tecentriq (atezolizumab) in first-line metastatic non-small cell lung cancer (NSCLC) showed improved response rates versus Tecentriq alone – including a notable improvement in high PD-L1-expressing tumors – and without adding significant toxicity.

The dual checkpoint inhibitor strategy could give Roche’s Tecentriq a critical boost in PD-1/L1 market share before competing combinations reach...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Conferences